Assessment of changes in patient function, measured by the health assessment questionnaire - Disability index (HAQ-DI), following daily subcutaneous (SC) injections of kineret (TM) (anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice population of patents with rheumatoid arthritis (RA) Conferences